Communiqués CellaVision AB

Actions

CEVI

SE0000683484

Equipement et technologie médicale avancés

PEA

Marché Fermé - Nasdaq Stockholm 18:00:00 12/08/2026			Varia. 5j.	Varia. 1 janv.
152,40 ^SEK	-1,55 %		+2,42 %	-3,05 %

20/07	Danske Bank relève l'objectif de cours de Cellavision à 187 couronnes (contre 180), maintient sa recommandation à l'achat - BN	FW
20/07	DNB Carnegie relève l'objectif de cours de CellaVision à 180 couronnes (contre 175), maintient sa recommandation à l'achat	FW

Communiqués

07/08	NOTICE OF EXTRAORDINARY GENERAL MEETING IN CELLAVISION AB (publ)	AQ
17/07	CellaVision : Sales recovery with all-time high in Americas	PU
14/07	CellaVision – Consensus estimates Q2 2026	AQ
03/07	Invitation to Presentation of the CellaVision Report for the Second Quarter 2026 on July 17, at 11:00 CEST	AQ
05/06	The Board of CellaVision AB appoints Steve Ferguson as CEO	AQ
28/04	Bulletin from the Annual General Meeting of CellaVision AB (publ)	AQ
24/04	Softer quarter due to lower sales in EMEA	AQ
21/04	CellaVision – Consensus estimates Q1 2026	AQ
16/04	The Nomination Committee’s proposals for the 2026 Annual General Meeting of CellaVision AB	AQ
10/04	Invitation to Presentation of the CellaVision Report for the First Quarter 2026 on April 24, at 11:00 CEST	AQ
01/04	CellaVision publishes its 2025 Annual and Sustainability Report	AQ
25/03	NOTICE OF ANNUAL GENERAL MEETING IN CELLAVISION AB (publ)	AQ
11/03	The new CellaVision® Bone Marrow Aspirate Application launches in EMEA	AQ
05/02	Solid Quarter driven by Strong Performance in Americas	AQ
02/02	CellaVision – Consensus estimates Q4 2025	AQ
22/01	Invitation to Presentation of the CellaVision Year-end Report 2025 on February 5, at 11:00 CET	AQ
12/12	CellaVision appoints Monica Jönsson as new CFO	AQ
08/12	CellaVision receives CE marking according to IVDR Class C for CellaVision® Bone Marrow Aspirate Application	AQ
06/11	Softer Quarter with Mixed Regional Performance	AQ
03/11	CellaVision – Consensus estimates Q3 2025	AQ
23/10/25	Invitation to Presentation of the CellaVision Report for the Third Quarter 2025 on November 6, at 11:00 CET	AQ
21/10/25	Nomination Committee for the CellaVision Annual General Meeting 2026	AQ
02/09/25	CellaVision : appoints Monica Jönsson as Interim CFO	PU
22/07/25	Cellavision Q2 2025 - Stable with Decent Growth	AQ
18/07/25	Robust Result with Mixed Regional Performance	AQ